# BPC-157 Legal Status, FDA 503A Category, and Compounding Access > BPC-157 legal status: FDA placed it in 503A Category 2 (effective Sept 29, 2023), it is not FDA-approved, and it is named on the July 2026 PCAC agenda under active review. General information, not legal advice. Where the regulatory picture stands today, and how legally compounded peptide access works in general. Present-tense facts, cited to FDA. Not legal or medical advice. ## Access is under active FDA review — and may expand in 2026 The forward-leaning fact first: the BPC-157 legal status is moving. BPC-157 is under active FDA evaluation, and access could change in 2026. The peptide — under the entries `BPC-157 (free base)` and `BPC-157 acetate` — is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [16]. The same agenda also lists KPV, TB-500, and MOTs-C [16]. That is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in current status. A PCAC discussion is advisory; the committee being scheduled to consider a substance means its evaluation is ongoing, not resolved [16]. No outcome of the July 2026 meeting can be assumed, stated, or dated. ## The current FDA fact: BPC-157 is in 503A Category 2 As it stands today, FDA placed BPC-157 in Category 2 for 503A compounding — bulk drug substances that may present significant safety risks. The placement took effect with FDA's September 29, 2023 update to the list of nominated bulk drug substances, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization [17]. Two consequences follow directly from that classification. First, as a Category 2 substance, BPC-157 is not within FDA's enforcement-discretion policy for 503A compounding — FDA stated it would consider taking action against a compounder using a Category 2 substance [17]. Second, and separately, BPC-157 is not an FDA-approved drug; approval of a finished drug is a different question from whether a bulk substance may be used in compounding, and BPC-157 has cleared neither bar [16][17]. ## How the 503A and 503B framework works Under the Federal Food, Drug, and Cosmetic Act, drug compounding runs through two sections. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered outsourcing facilities that may compound larger batches under cGMP-style oversight and FDA registration and inspection [16]. A compounder may use a bulk drug substance only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. Substances not yet on a bulks list are evaluated through a public nomination process with input from PCAC, and inclusion on a final list is decided by FDA rulemaking — being discussed by PCAC is a step in evaluation, not a final listing decision [16]. For substances FDA placed in Category 2, the agency has stated they are not afforded enforcement discretion even if nominations are updated [16]. ## How legally compounded access works in general In the United States, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [16]. The preparation is then made by a state-licensed 503A compounding pharmacy or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [16]. Telehealth can serve as the front-end channel for the prescriber-evaluation step — a route to a licensed-prescriber consultation and prescription. It does not change which substances are eligible to be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription [16]. The ingredient-eligibility caveat is the binding one here: a compounder may use a requested active ingredient only if it is eligible under the 503A and 503B rules, and an ingredient FDA has flagged for significant safety risks — a Category 2 substance — is not eligible for routine 503A compounding while that status stands [16][17]. This site names no pharmacy, clinic, telehealth provider, or vendor, provides no dosing, and describes no way to obtain a restricted substance outside the lawful framework. ## What this page does not assert To keep the record honest, several things circulating online are deliberately excluded here because they could not be confirmed from an authoritative FDA source. This page does not assert that BPC-157 has been reclassified, removed from Category 2, or moved back toward Category 1, and it attaches no future date to any predicted FDA outcome. Reports of an early-2026 reclassification of roughly fourteen peptides, and vendor claims that BPC-157 was "removed" from Category 2 in 2026, are unconfirmed pending matters — the FDA PCAC agenda still listing BPC-157 for July 2026 is consistent with its evaluation being ongoing rather than resolved [16]. Everything above is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance. --- A bioluminescent field-station readout of the BPC-157 literature — every figure logged to its source, no clinic in the canopy and nothing here for sale.